Skip to main content

Table 2 The comparison of 24 months survival and cyclin D1 expression in selected groups of patients.

From: Galectin-3 and cyclin D1 expression in non-small cell lung cancer

Survival Positive
Cyclin D1
expression n (%)
Negative
Cyclin D1
expression n (%)
Chi2
Yatesa
p Cox Mantel
All examinated patients with NSCLC
< 24 months 16 (41.03%) 4 (50%) 0.01 0.940 0.624
≥ 24 months 23 (58.97%) 4 (50%)    
The patients with squamous cell carcinoma
< 24 months 8 (38.10%) 2 (66.67%) 0.10 0.754 0.234
≥ 24 months 13 (61.90%) 1 (33.33%)    
The patients with adenocarcinoma
< 24 months 7 (58.33%) 1 (33.33%) 0.02 0.897 0.396
≥ 24 months 5 (41.67%) 2 (66.67%)    
Stage II      
< 24 months 4 (100%) 1 (25%) 2.13 0.144 0.076
≥ 24 months 0 (0%) 3 (75%)    
Stage III      
< 24 months 6 (42.86%) 1 (50%) 0.33 0.567 0.544
≥ 24 months 8 (57.14%) 1 (50%)    
Stage IV      
< 24 months 3 (75%) 2 (100%) 0.15 0.698 0.085
≥ 24 months 1 (25%) 0 (0%)